Damora Therapeutics (DMRA)
NASDAQ:DMRA
DMRA Stock Chart & Stats
$24.40
-$0.21(-3.82%)
At close: 4:00 PM EST
$24.40
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.01 - $38.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.26M
Market Cap
$1.47B
Enterprise Value$1.21B
Total Cash (Recent Filing)$257.62M
Total Debt (Recent Filing)$68.00K
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Apr 24, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.24
Shares Outstanding60,303,210
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.02
Forecast
1Y Price Target
$44.00Price Target Upside80.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Administration BenefitLead candidate DMR-001 is designed for subcutaneous administration with potent activity against both major CALR mutant types, offering a practical dosing advantage compared with an intravenous-only competitor.
Balance Sheet And Pipeline SupportAn acquisition combined with concurrent financing strengthened the balance sheet and supports advancement of a multimodal pipeline targeting mutant CALR-driven blood cancers beyond a single asset.
Clinical And Regulatory MilestonesRegulatory filings and planned proof-of-concept clinical data for the lead candidate could enable a rapid move into late-stage development if results are favorable, creating clear clinical milestones for the stock to react to.
Bears Say
Advanced Competitor ProgramAn established competitor has a more advanced mutCALR program, which could constrain market opportunity even if DMR-001 demonstrates advantages.
Direct Competition From Larger FirmIncyte's development of both a mutant CALR-directed monoclonal antibody and a bispecific T-cell engager presents direct competition that could limit adoption of Galecto's candidate.
First-mover Clinical ProgressA first-mover rival has demonstrated clinical progress targeting the same mutation, increasing the hurdle for market entry and patient adoption by later entrants.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.01 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.47B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Apr 24, 2026 which is in 16 days.
How were Damora Therapeutics’s earnings last quarter?
Damora Therapeutics released its earnings results on Mar 30, 2026. The company reported -$3.243 earnings per share for the quarter, missing the consensus estimate of $0.902 by -$4.145.
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 60,303,210 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Damora Therapeutics reported an EPS of -$3.243 in its last earnings report, missing expectations of $0.902. Following the earnings report the stock price went up 6.716%.
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (80.33% Upside)
$44.00 (80.33% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-134.39%
Trailing 12-Months
Asset Growth
-54.07%
Trailing 12-Months
Company Description
Damora Therapeutics
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
DMRA Stock 12 Month Forecast
Average Price Target
$44.00
▲(80.33% Upside)
Technical Analysis
Ownership Overview
15.51% Insiders
0.31% Mutual Funds
0.90% Other Institutional Investors
83.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---